<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: Confirmed ulcerative colitis | Management | Ulcerative colitis | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers the management of confirmed ulcerative colitis in primary care."/><meta data-react-helmet="true" property="og:description" content="Covers the management of confirmed ulcerative colitis in primary care."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/ulcerative-colitis/management/confirmed-ulcerative-colitis/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: Confirmed ulcerative colitis | Management | Ulcerative colitis | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/ulcerative-colitis/management/confirmed-ulcerative-colitis/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">Ulcerative colitis</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: Confirmed ulcerative colitis</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/ulcerative-colitis/","name":"Ulcerative colitis"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/ulcerative-colitis/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: Confirmed ulcerative colitis"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">Ulcerative colitis: </span><span>Scenario: Confirmed ulcerative colitis</span></h1><p class="page-header__lead"><span>Last revised in April2020</span></p></div><p class="visually-hidden">Covers the management of confirmed ulcerative colitis in primary care.</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="Ulcerative colitis chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Diagnosis"><a aria-current="false" href="../../diagnosis/index.html"><span class="stacked-nav__content-wrapper">Diagnosis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Suspected ulcerative colitis"><a aria-current="false" href="../suspected-ulcerative-colitis/index.html"><span class="stacked-nav__content-wrapper">Scenario: Suspected ulcerative colitis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Confirmed ulcerative colitis"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: Confirmed ulcerative colitis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis"><a aria-current="false" href="../fertility-pregnancy-breastfeeding-with-ulcerative-colitis/index.html"><span class="stacked-nav__content-wrapper">Scenario: Fertility, pregnancy, and breastfeeding with ulcerative colitis</span></a></li><li class="stacked-nav__list-item" data-tracking="Management | Scenario: COVID-19"><a aria-current="false" href="../covid-19/index.html"><span class="stacked-nav__content-wrapper">Scenario: COVID-19</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#review-in-primary-care">Review in primary care</a><ol aria-label="Sections within Review in primary care" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#specialist-treatments">Specialist treatments</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-53c">Basis for recommendation</a></li></ol></li><li><a href="index.html#management-of-a-flare-up">Management of a flare-up</a><ol aria-label="Sections within Management of a flare-up" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#disease-severity-assessment-tools">Disease severity assessment tools</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4f4">Basis for recommendation</a></li></ol></li><li><a href="index.html#management-of-symptoms">Management of symptoms</a><ol aria-label="Sections within Management of symptoms" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-2ef">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="confirmed-ulcerative-colitis" class="ChapterBody-module--wrapper--2HCfk "><h2 id="confirmed-ulcerative-colitis" class="visually-hidden">Scenario: Confirmed ulcerative colitis</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a656b2d1-a9e6-4ad3-9792-528cdf6e124d --><!-- begin field 7ba9436a-ae0a-47a3-9964-acbd0087ce68 --><p>From age 6 months onwards.</p><!-- end field 7ba9436a-ae0a-47a3-9964-acbd0087ce68 --><!-- end item a656b2d1-a9e6-4ad3-9792-528cdf6e124d --></div><section aria-labelledby="review-in-primary-care" class="ChapterBody-module--wrapper--2HCfk "><h3 id="review-in-primary-care">How should I review a person with confirmed ulcerative colitis in primary care?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item c22cdf5c-70f4-436b-bb54-9cd726d8ec73 --><!-- begin field 182e701e-a4de-4cbe-8acc-9c5d28957ea6 --><p><strong>If a person has a <a class="topic-reference internal-reference" href="../suspected-ulcerative-colitis/index.html#specialist-investigations">confirmed</a> diagnosis of ulcerative colitis, arrange regular reviewsin primary care, the frequency depending on clinical judgement.</strong></p><ul><li>Assessthe impact of<a class="topic-reference internal-reference" href="../../diagnosis/diagnosis/index.html">symptoms</a>on daily functioningsuch as home, work, school, and leisure activities, and assess for associated anxiety and/ordepression. See the CKS topics on<a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>,<a class="topic-reference external-reference" href="../../../depression-in-children/index.html">Depression in children</a>, and<a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a>for more information.</li><li>Provide advice on ulcerative colitis and offer sources of information and support.<ul><li>Explain that ulcerative colitisis a lifelong condition, which may haveunpredictable relapses and remissions. Specialist drug treatments aim to induce remission of the disease and to treat symptoms, and occasionally surgical intervention may be necessary.</li><li>Encourage healthy lifestyle measures, including maintaining a healthy weight and taking regular exercise if possible. See the CKS topic on<a class="topic-reference external-reference" href="../../../obesity/index.html">Obesity</a> for more information.</li><li>Crohn's and Colitis UK is a national charity that provides support for people with ulcerative colitis and their families (website available at <a data-hyperlink-id="5a40af20-1922-4b2c-b229-aa160136c896" href="https://www.crohnsandcolitis.org.uk/" target="_blank">www.crohnsandcolitis.org.uk</a>; telephone information service and emotional support helpline0300 2225700). Itpublishes a range of <a data-hyperlink-id="715ccf0d-df6f-487d-97ee-aa160136c967" href="https://www.crohnsandcolitis.org.uk/about-inflammatory-bowel-disease/publications" target="_blank">information sheets and booklets</a>including <a data-hyperlink-id="5f40c737-a57e-43ab-9a02-aa160136ca32" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/ulcerative-colitis.pdf" target="_blank">Ulcerative colitis. Your guide</a>and <a data-hyperlink-id="b4544c7e-0955-434f-a091-aa160136ca43" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/IBD-in-children.pdf" target="_blank">IBD in children: a parent's guide</a>, and provides informationon managing symptoms, drug treatments, diet, pregnancy, education, employment, and travel.</li><li>CICRA (Crohn's in Childhood Research Association) is a national charity that supports children and young people with inflammatory bowel disease (website available at <a data-hyperlink-id="c8595d77-b6a6-4a1a-82af-aa160136ca52" href="https://www.cicra.org/" target="_blank">www.cicra.org</a>), and provides patient information and young people's forums for peer support.</li></ul></li><li>Assess the person's risk of osteoporosis,including dietary calcium intake,and manage appropriately. See the CKStopic on<a class="topic-reference external-reference" href="../../../osteoporosis-prevention-of-fragility-fractures/index.html">Osteoporosis - prevention of fragility fractures</a>for more information.<ul><li>The Crohn's and Colitis UK patient informationsheet<a data-hyperlink-id="570595f2-06b4-40e4-98a7-a98e0144fc58" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/bones-and-IBD.pdf" target="_blank">Bones and IBD</a>may be helpful.</li></ul></li><li>Ensurethe person has follow-up arranged with a gastroenterologist and/or specialist nurse if appropriate, and encourage the person to attend appointments regularly.<ul><li>Ensure the person is aware of the need for<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">colorectal cancer</a>surveillance, and hascolonoscopy screening arranged by the specialist team if diagnosed10 years agoor more (with the exception of those withconfirmed proctitis alone).The frequency of subsequent monitoring is a specialist decision, depending on the severity and duration of colitis, presence of co-morbid conditions, and the appearances at colonoscopy. The Crohn's and Colitis UK patient informationsheet <a data-hyperlink-id="a2ff7771-212b-4ca1-b956-aa160136cae9" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/bowel-cancer-and-IBD.pdf" target="_blank">Bowel cancer and IBD</a>may be helpful.</li><li>Ensure that children and young people have their growth (height and weight) and pubertal development monitored regularly.</li></ul></li><li>Prescribe and monitor <a class="topic-reference internal-reference" href="index.html#specialist-treatments">specialist drug treatments</a>ifashared-care agreement is in place, if appropriate, and encourage the person to take medication regularly as prescribed.<ul><li>Monitoring may includechecking serum ferritin, vitamin B<sub>12</sub>, folate, calcium, and vitamin D levels, and arranging supplementation where appropriate. See the CKS topics on<a class="topic-reference external-reference" href="../../../anaemia-iron-deficiency/index.html">Anaemia - iron deficiency</a>,<a class="topic-reference external-reference" href="../../../anaemia-b12-folate-deficiency/index.html">Anaemia - B12 and folate deficiency</a>,<a class="topic-reference external-reference" href="../../../vitamin-d-deficiency-in-adults-treatment-prevention/index.html">Vitamin D deficiency in adults - treatment and prevention</a>, and<a class="topic-reference external-reference" href="../../../vitamin-d-deficiency-in-children/index.html">Vitamin D deficiency in children</a>for more information.</li><li>Note: specialist drug treatment for the induction and maintenance of remission in ulcerative colitis should always be initiated by a specialist. If there are any uncertainties regarding adverse effects or safety of drug treatments, seek specialist advice.</li></ul></li><li>Assess for clinical featuressuggesting a <a class="topic-reference internal-reference" href="index.html#management-of-a-flare-up">flare-up</a>of ulcerative colitisor other troublesome <a class="topic-reference internal-reference" href="index.html#management-of-symptoms">symptoms</a>,and manage appropriately. Consider checking:<ul><li>The person's body mass index (BMI) for unintended weight lossor signs of malnutrition.</li><li><a class="topic-reference internal-reference" href="../../diagnosis/investigations/index.html">Serum inflammatory markers</a>if a flare-up is suspected, as a raised levelmay indicate an acute severe episode requiring hospital admission. See the section on<a class="topic-reference internal-reference" href="index.html#management-of-a-flare-up">Management of a flare-up</a>for more information.</li></ul></li><li>Arrange a referral to:<ul><li>An appropriate specialist team (such as rheumatology, dermatology, or ophthalmology) if appropriate,if there are suspected <a class="topic-reference internal-reference" href="../../background-information/extra-intestinal-manifestations/index.html">extra-intestinal manifestations</a>.</li><li>A colorectal surgeon if<a class="topic-reference internal-reference" href="index.html#management-of-a-flare-up">surgical intervention</a>may be needed or there is a suspected post-operative <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">complication</a>.</li><li>A stoma nurse if the person has an ileostomy andthere are troublesome symptoms post-operatively, depending on clinical judgement.</li><li>A dietitian if there are signs of unintended weight loss or malnutrition.</li></ul></li><li>Ensure the person receives appropriate vaccinations regularly, due to theincreased risk of influenza and pneumococcal infection. See the CKStopics on<a class="topic-reference external-reference" href="../../../immunizations-seasonal-influenza/index.html">Immunizations - seasonal influenza</a>and<a class="topic-reference external-reference" href="../../../immunizations-pneumococcal/index.html">Immunizations - pneumococcal</a>for more information.<ul><li>Advise that if theperson is taking <a class="topic-reference internal-reference" href="index.html#specialist-treatments">immunosuppressive or biologic therapy</a>, live vaccines are contraindicated, and these vaccinesshould only be given before the start of specialist treatment, or else postponed for at least 6months after stopping this therapy. See the CKS topic on<a class="topic-reference external-reference" href="../../../dmards/index.html">DMARDs</a> for more information.</li></ul></li></ul><!-- end field 182e701e-a4de-4cbe-8acc-9c5d28957ea6 --><!-- end item c22cdf5c-70f4-436b-bb54-9cd726d8ec73 --></div><section aria-labelledby="specialist-treatments" class="ChapterBody-module--wrapper--2HCfk "><h4 id="specialist-treatments">Specialist treatments</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dc9e4ee0-00ce-4923-9a13-aa15015ff9a8 --><!-- begin field 0a65173b-bfc1-43f9-8d78-aa15015ff9d2 --><ul><li><strong>Specialist drug treatment for ulcerative colitis is generally givenfor inductionand maintenance of remission.Individualized treatment optionsdepend on the severity,extent, and patternof disease, previous response to treatment, and the person'spreferences.</strong><ul><li>Aminosalicylates  mesalazine and sulfasalazine may be considered for a mild-to-moderate first presentationor inflammatory exacerbation of proctitis, proctosigmoiditis, or left-sided ulcerative colitis. These drugs are also effective at maintainingremission. They are often prescribed topically (suppository or enema) initially, andorally if remission is not achieved within four weeks. For extensive disease, topical and high-dose oral treatment may be offered first-line.</li><li>Corticosteroids monotherapy with a time-limited course of corticosteroidsmay beused for induction of remission if aminosalicylates are ineffective or not tolerated, with theaim to gradually taper the dose according to disease severity and the person's response to treatment. They should not be used to maintain clinical remissiondue to the risk of multiple adverse effects with long-term use. They may be prescribed topically, orally, or intravenously.<ul><li>The term 'corticosteroid dependency'usually relates to people with ulcerative colitiswho are unable to stop corticosteroids within 3 months without recurrent active disease, or who have a relapse requiring corticosteroids within 3 months of stopping them.</li></ul></li><li>Calcineurin inhibitors  tacrolimus or ciclosporinmay be added to oral corticosteroids to induce remission in people with mild to moderate disease if there is an inadequate response to oral corticosteroids after 24 weeks.Intravenous ciclosporin may be used for acute severe disease, especially if intravenous corticosteroids are not effective, contraindicated, or not tolerated.</li><li>Immunosuppressive drugs  thethiopurines (azathioprine, mercaptopurine) ormethotrexate (second-line) may be considered to maintain remission if there are two or more inflammatory exacerbations in a 12-month period that require treatment with oral corticosteroids, or if remission cannot be maintained by aminosalicylates.<ul><li>Note: thiopurines may increase the risk of non-melanoma skin cancer, and peopleshould be monitored for skin cancer and given appropriate sun protection advice.</li></ul></li><li>Biologic therapy the anti-tumour necrosis factor (TNF)-alpha monoclonalantibody agents intravenous infliximab and subcutaneous adalimumab and golimumab are effective at inducing remission in people with severe active disease which has not responded to conventional therapy, or where conventional therapy is not tolerated. These drugs are also effective at maintainingremission.</li><li>For more detailed prescribing information, see the CKS topics on<a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a>and<a class="topic-reference external-reference" href="../../../dmards/index.html">DMARDs</a>.</li></ul></li><li><strong>Specialist enteral nutritional supplementationmay be used as an alternativetoconventional therapyin some children for induction of remission, such as:</strong><ul><li>If oral feeding is not tolerated orif there is an acute severe flare-up with associated malnutrition.</li><li>If there is faltering growth or development, or if there areconcerns about adverse effects of corticosteroids.</li></ul></li></ul><p>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]</p><!-- end field 0a65173b-bfc1-43f9-8d78-aa15015ff9d2 --><!-- end item dc9e4ee0-00ce-4923-9a13-aa15015ff9a8 --></div></section><section aria-labelledby="basis-for-recommendation-53c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-53c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 53c2b7ad-65d0-48e5-bc50-b29ba025383f --><!-- begin field 0adf2605-960d-4611-95b6-fc5492dd0cf4 --><p>Therecommendations on review in primary care are based on the National Institute for Health and Care Excellence (NICE) clinical guidelines <em>Ulcerative Colitis:management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]  and <em>Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomas</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2011</a>]; the European Crohn's and Colitis Organisation (ECCO) consensus guidelines<em>Third European evidence-based consensus ondiagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>], <em>Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>],<em>European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Dignass, 2015</a>],<em>The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2016</a>],<em>European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Annese, 2015</a>], and<em>Practical guideline for fatigue management in inflammatory bowel disease</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>]; thejoint ECCO andEuropean Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) evidence-based guidelines<em>Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>]and <em>Management of Paediatric Ulcerative Colitis, Part 2: Acute severe colitis</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>];the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline<em>Clinical nutrition in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>];the British Society of Gastroenterology (BSG)<em>Guidelines for the management of inflammatory bowel disease in adults</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>],the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition (BSPGHAN) consensus document<em>Guidelines for the management of inflammatory bowel disease in children in the United Kingdom</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">British Society of Paediatric Gastroenterology, 2010</a>], and expert opinion inreview articles on ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>] and inflammatory bowel disease in children[<a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</p><h5>Assessing the impact of symptoms</h5><ul><li>This recommendation is based on the observation in the BSGguidelinethatthe incidence of anxiety and depression is higher in people with inflammatory bowel disease than in control populations [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and is supported by expert opinion in review articles thatinflammatory bowel disease can adversely affect psychosocial functioning [<a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</li><li>The joint ECCO/ESPGHAN guidelinerecommends that psychological support should be available for children with a confirmed diagnosis of ulcerative colitis, as this may improve quality of life and wellbeing[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>].</li><li>Expert opinion in a review article notes that symptoms such as fatigue, decreased energy levels, and reduced appetite should not be assumed to be secondary to inflammatory bowel disease, as they may reflect an underlying mood disorder [<a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</li></ul><h5>Offering information and support</h5><ul><li>Therecommendation to offer information and supportis based on the NICE clinical guideline on ulcerative colitis[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>] and the BSGguideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>].<ul><li>NICE states that advice and support for people with ulcerative colitis is important and should include information on the effects of the condition and its course, medical treatment options, the effects of drug treatment, and the monitoring required.</li></ul></li><li>The recommendation to encourage healthy lifestyle measures including regular exercise is based on the guideline on fatigue management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>]and the joint ECCO/ESPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], which highlight potential benefits for fatigue management, growth, and bone health.</li></ul><h5>Assessing osteoporosis risk</h5><ul><li>Therecommendation to monitor bone health and assess osteoporosis riskis based on the NICE clinical guideline on ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], thejoint ECCO/ESPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], the BSPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">British Society of Paediatric Gastroenterology, 2010</a>], and the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>].<ul><li>The NICE guideline development group notesan increased risk of osteoporosis in people with ulcerative colitis compared with the general population, especially during disease relapse, with persistent disease, and when taking corticosteroids. It recommendsmonitoring bone health in children and young people with ulcerative colitis during chronic active disease, after recurrent active disease, and after treatment with oral corticosteroids.</li><li>In addition, potentially poor nutritional status due toreduced micronutrient intake and absorptionmay havea significant impact on bone status in children [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>].</li><li>The BSPGHAN guideline recommends ensuring an adequate intake of calcium and vitamin D, and considering supplementation if this is insufficient.</li></ul></li></ul><h5>Ensuring specialist follow-up and surveillance</h5><ul><li>The BSG guideline states that people with inflammatory bowel diseaseshould be cared for by a defined multidisciplinaryteam including gastroenterologists, colorectal surgeons, nurse specialists, a dietitian, pharmacist, and gastrointestinal radiologist. This should allow for early initiation of appropriate therapy and ongoing assessment of disease progress and any adverse effects of treatment[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>].</li><li>The recommendations on colonoscopic surveillance for colorectal cancer are based on the NICE guideline on colonoscopic surveillance [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2011</a>], the ECCO consensus guidelines on diagnosis and management[<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>]and malignancies [<a class="bibliography-reference internal-reference" href="../../references/index.html">Annese, 2015</a>], and expert opinion inreview articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>].<ul><li>The risk of colorectal cancer in people with ulcerative colitis is increased compared with the general population, and is particularly associated with increaseddisease duration, disease extent, and more severe or persistent inflammatory activity. In addition, afamily history of colorectal cancerand the presence of co-morbid primary sclerosing cholangitis increases the risk further [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Annese, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li><li>Surveillance colonoscopy may allow earlier detection and potentially prevent progression to colorectal cancer, thereby improvingprognosis[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li></ul></li><li>The recommendations on monitoring a child or young person'sgrowth and pubertal development are based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>],thejoint ECCO/ESPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], and expert opinion inreview articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].<ul><li>The NICE guideline development group noted that children and young people with ulcerative colitis are at risk of growth and pubertal delay, especially during relapse, persistent disease, when approaching puberty, and when taking corticosteroids. Monitoring growth and pubertal development by professionals with appropriate expertise is therefore recommended, as restricted growth or pubertal delay can impact on the child or young person's social and emotional development.</li><li>This approach is supported by expert opinion in a review article, which states that children with inflammatory bowel disease are at risk of macro- and micronutrient deficiencies, with weight loss occurring in 34% of children with ulcerative colitis. Delayed skeletal maturation and growth failure may sometimes lead to delayed puberty[<a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</li><li>The joint ECCO/ESPGHAN guideline notes that growth impairment is rare in children with ulcerative colitis who are not corticosteroid-dependent.</li></ul></li></ul><h5>Prescribing and monitoring drug treatments</h5><ul><li>The recommendation on ensuring appropriate monitoring of drug treatments is based on the NICE clinical guideline on ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], thejoint ECCO/ESPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</li><li>Therecommendation on monitoring for nutritional deficiencies is based on the ECCO consensus guidelines on diagnosis and management[<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>] and iron deficiency and anaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dignass, 2015</a>], the ESPEN guideline on nutrition [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>], the joint ECCO/ESPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], a guideline on fatigue management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>], andexpert opinion inreview articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].<ul><li>The ECCO consensus guideline notes that anaemia is the most common systemic complication and extra-intestinal manifestation of inflammatory bowel disease, and recommends that all people with inflammatory bowel disease should be assessed foranaemiaregularlybecause of its high prevalence and potential impact on quality of life. It also notes that recurrent anaemia may indicate persistent disease activity even if there is clinical remission and serum inflammatory markers are normal [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dignass, 2015</a>].</li><li>People with inflammatory bowel disease are at increased risk of malnutrition and nutritional deficiencies due to gut loss from diarrhoea, chronic inflammation, and inadequate dietary intake due to reduced appetite accompanying disease activity, and people should be checked for nutritional deficiencies regularly[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>]. In addition, 'backwash ileitis'is observed in up to 20% of people with extensive colitis which may affect small bowel nutrient absorption [<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li><li>Expert opinion in a review article notes that recognition and treatment of iron deficiency and other nutritional deficits is important for the general wellbeing of children with ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>].</li><li>The joint ECCO/ESPGHAN guideline notes that vitamin D should be supplemented in children if deficiency is identified, regardless of corticosteroid use [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>].</li></ul></li></ul><h5>Assessing for clinical features of relapse or troublesome symptoms</h5><ul><li>The recommendation on checking the person's body mass index (BMI) is extrapolated fromthe ESPEN guideline on nutrition, which states that as people with inflammatory bowel disease are at increased risk of malnutrition, they should be screened for this on a regular basis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>].<ul><li>People with malnutrition have a worse prognosis, are more likely to be hospitalized, are at increased risk of infection and venous thromboembolism, and have increased mortality rates compared with people who are not malnourished. In addition, malnourished children are at increased risk of growth failure and delayed pubertal development.</li><li>Malnutrition may be the result of reduced oral intake, increased nutrient requirements, and increased gastrointestinal losses. People with ulcerative colitisare more at risk when the disease is active.</li></ul></li><li>The recommendation on checking serum inflammatory markers is based on the ECCO consensus guideline on management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>], the joint ECCO/ESPGHAN guideline on acute severe disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>].</li></ul><h5>Arranging specialist referral</h5><ul><li>The recommendation to arrange referral if there are suspected extra-intestinal manifestations is extrapolated from the ECCO consensus guideline on extra-intestinal manifestations[<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2016</a>]andthe BSGguideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.<ul><li>The ECCO consensus guideline notes that the managementof complex extra-intestinal manifestations should be discussed in a multi-disciplinary team setting.</li></ul></li><li>The recommendations to arrange referral to a colorectal surgeon and/or stoma nurse have been extrapolated from the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]. They arealso pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation to considerreferral to a dietitian is extrapolated from the ESPEN guideline, which states that nutritional care is important, particularly in children, to promote optimal growth and pubertal development [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>].</li></ul><h5>Advice on vaccinations</h5><ul><li>These recommendations are based on the ECCO consensus guideline on diagnosis and management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>], the BSGguideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and expert opinion in a review article[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>].<ul><li>People with ulcerative colitis may be at increased risk of opportunistic infections due to underlying disease activity, malnutrition, long-term immunosuppressive drug treatment, or surgery [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li></ul></li></ul><!-- end field 0adf2605-960d-4611-95b6-fc5492dd0cf4 --><!-- end item 53c2b7ad-65d0-48e5-bc50-b29ba025383f --></div></section></section><section aria-labelledby="management-of-a-flare-up" class="ChapterBody-module--wrapper--2HCfk "><h3 id="management-of-a-flare-up">Management of a flare-up</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d6df3217-89b3-4e3d-9aa7-aa150160c489 --><!-- begin field 014c619f-ac96-45e5-a6d0-aa150160c4ae --><ul><li><strong>Arrange an emergency hospital admission if the personhas a suspected flare-up of ulcerative colitis.</strong> Consider using a <a class="topic-reference internal-reference" href="index.html#disease-severity-assessment-tools">disease severity assessment tool</a>. Clinical features of acute severe disease include:<ul><li>Severe diarrhoea, nocturnal diarrhoea, or bloody diarrhoea(more than 68 stools a day).</li><li>Fever, dehydration,tachycardia, or hypotension.</li><li>Severe abdominal pain or suspected <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">intestinal obstruction</a>.</li><li>Signs of malnutrition with a body mass index (BMI) less than 18.5 kg/m<sup>2</sup>, or unintended suddenweight loss.</li><li>Raised<a class="topic-reference internal-reference" href="../../diagnosis/investigations/index.html">inflammatory markers</a> and/or anaemia.</li><li>Persistent symptoms despiteoptimal management in primary care.</li></ul></li><li><strong>If admission to hospital is not needed:</strong><ul><li>Consider whether symptoms may be due to an <a class="topic-reference internal-reference" href="../../diagnosis/differential-diagnosis/index.html">alternative condition</a>such as <em>Clostridium difficile</em> infection, and manage appropriately.</li><li>Check the person's adherence to their current drug treatment regimen, and encourage them to take medication regularly and appropriately.</li><li>Consider arranging an urgent specialist gastroenterology review appointment or seeking specialist advice.<ul><li>Consider prescribing drug treatment for disease flare-ups according to the person's shared-care agreement,such asstarting a time-limitedcourse of <a class="topic-reference internal-reference" href="index.html#specialist-treatments">oral corticosteroids</a>, if appropriate, whilst awaiting specialist review. Note: corticosteroids should not be used to maintain disease remission. See the CKS topic on<a class="topic-reference external-reference" href="../../../corticosteroids-oral/index.html">Corticosteroids - oral</a> for more prescribing information.</li><li>Do not prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) if there is suspected acute severe colitis.</li></ul></li><li>Consider arranging a referral to a dietitian if there are signs of unintended weight loss or malnutrition.</li></ul></li><li><strong>If there are recurrent flares of disease activity, seek specialist advice</strong> regarding whether the person's maintenance treatment regimen needs to be changed to improve disease control, or whether surgerymay be needed.</li></ul><!-- end field 014c619f-ac96-45e5-a6d0-aa150160c4ae --><!-- end item d6df3217-89b3-4e3d-9aa7-aa150160c489 --></div><section aria-labelledby="disease-severity-assessment-tools" class="ChapterBody-module--wrapper--2HCfk "><h4 id="disease-severity-assessment-tools">Disease severity assessment tools</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0b35ceb6-1796-4526-a6b8-aa1b010f7eec --><!-- begin field 1167d432-01a0-4253-90e0-aa1b010f7f56 --><p><strong>Table 1.</strong>Truelove and Witts' severity index for assessing severity of ulcerative colitis in adults.</p><table><thead><tr><th colspan="1"><p></p></th><th colspan="1"><p>Mild</p></th><th colspan="1"><p>Moderate</p></th><th colspan="1"><p>Severe</p></th></tr></thead><tbody><tr><td colspan="1">Bowel movements (number per day)</td><td colspan="1">Fewer than 4</td><td colspan="1">46</td><td colspan="1">6 or more plus at least one of the features of systemic upset (marked with *)</td></tr><tr><td colspan="1">Blood in stools</td><td colspan="1">No more than small amounts of blood</td><td colspan="1">Between mild and severe</td><td colspan="1">Visible blood</td></tr><tr><td colspan="1">Pyrexia (temperature greater than 37.8C)*</td><td colspan="1">No</td><td colspan="1">No</td><td colspan="1">Yes</td></tr><tr><td colspan="1">Pulse rate greater than 90 beats per minute*</td><td colspan="1">No</td><td colspan="1">No</td><td colspan="1">Yes</td></tr><tr><td colspan="1">Anaemia*</td><td colspan="1">No</td><td colspan="1">No</td><td colspan="1">Yes</td></tr><tr><td colspan="1">Erythrocyte sedimentation rate (mm/hour)*</td><td colspan="1">30 or below</td><td colspan="1">30 or below</td><td colspan="1">Above 30</td></tr><tr><td colspan="4"><strong>Data from:</strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]</td></tr></tbody></table><p><strong>Table 2.</strong> Paediatric Ulcerative Colitis Activity Index (PUCAI) for assessing severity of ulcerative colitis in children and young people.</p><table><thead><tr><th scope="col"></th><th scope="col">Points</th></tr></thead><tbody><tr><td><strong>Abdominal pain</strong></td><td></td></tr><tr><td>No pain</td><td>0</td></tr><tr><td>Pain can be ignored</td><td>5</td></tr><tr><td>Pain cannot be ignored</td><td>10</td></tr><tr><td><strong>Rectal bleeding</strong></td><td></td></tr><tr><td>None</td><td>0</td></tr><tr><td>Small amount only, in less than 50% of stools</td><td>10</td></tr><tr><td>Small amount with most stools</td><td>20</td></tr><tr><td>Large amount (50% of the stool content)</td><td>30</td></tr><tr><td><strong>Consistency of most stools</strong></td><td></td></tr><tr><td>Formed</td><td>0</td></tr><tr><td>Partially formed</td><td>5</td></tr><tr><td>Completely unformed</td><td>10</td></tr><tr><td><strong>Number of stools in 24 hours</strong></td><td></td></tr><tr><td>02</td><td>0</td></tr><tr><td>35</td><td>5</td></tr><tr><td>68</td><td>10</td></tr><tr><td>More than 8</td><td>15</td></tr><tr><td><strong>Nocturnal stools (any episode causing wakening)</strong></td><td></td></tr><tr><td>No</td><td>0</td></tr><tr><td>Yes</td><td>10</td></tr><tr><td><strong>Activity level</strong></td><td></td></tr><tr><td>No limitation of activity</td><td>0</td></tr><tr><td>Occasional limitation of activity</td><td>5</td></tr><tr><td>Severe restricted activity</td><td>10</td></tr><tr><td colspan="2"><strong>Remission (disease not active):</strong> below 10 points <strong>Mild:</strong> 1034 points <strong>Moderate:</strong> 3564 points <strong>Severe:</strong> 65 points or more</td></tr><tr><td colspan="2"><strong>Data from:</strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]</td></tr></tbody></table><!-- end field 1167d432-01a0-4253-90e0-aa1b010f7f56 --><!-- end item 0b35ceb6-1796-4526-a6b8-aa1b010f7eec --></div></section><section aria-labelledby="basis-for-recommendation-4f4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4f4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4f478c7c-8a4e-4528-85d2-aa150160c4b2 --><!-- begin field 920ba5a6-dde7-41b4-ab08-aa150160c4b2 --><p>Therecommendations on management ofsuspected acute severe disease are largely based onthe National Institute for Health and Care Excellence (NICE) clinical guideline<em>Ulcerative Colitis: management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the European Crohn's and Colitis Organisation (ECCO) consensus guidelines<em>Third European evidence-based consensus ondiagnosis and management of ulcerative colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>],<em>Third European evidence-based consensus ondiagnosis and management of ulcerative colitis. Part 2: current management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>], and<em>Practical guideline for fatigue management in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>];the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline<em>Clinical nutrition in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>], twojoint ECCO andEuropean Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) evidence-based guidelines<em>Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>] and <em>Management of Paediatric Ulcerative Colitis, Part 2: Acute severe colitis</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>];the British Society of Gastroenterology (BSG)<em>Guidelines for the management of inflammatory bowel disease in adults</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and expert opinion inreview articles on ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>]and inflammatory bowel disease in children [<a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>].</p><h5>Clinical features of acute severe disease</h5><ul><li>The information on clinical features suggesting acute severe disease are based on the NICE clinical guideline[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the ECCO consensus guideline on management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>], the joint ECCO/ESPGHAN guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>],the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and expert opinion inreview articles [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>].<ul><li>Use of a disease severity scoring tool may help to distinguish people with severe symptoms needing hospital admission from people with mild or moderately active disease who need outpatient clinic referral[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>].</li><li>The ECCO consensus guideline on management notes that the Truelove and Witt severity index remains the best validated and most widely used scoring tool. Bloody diarrhoea is a key clinical feature, with one additional parameter needed to define a severe flare-up of disease[<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>]. The body mass index (BMI) parameter is based on the ESPEN guideline on nutrition which states that this value reflects undernutrition and disease-associated catabolism [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>]. CKS notes that raised inflammatory markers including C-reactive protein (CRP) in addition to erythrocyte sedimentation rate (ESR) citedin the Truelove and Witt severity index, may be used to help identify acute severe disease activity[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>].</li><li>The NICE clinical guidelineand the ECCO/ESPGHAN guidelinerecommend using the Paediatric Ulcerative Colitis Activity Index (PUCAI) to monitor disease activity when children are reviewed [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>]. Repeat PUCAI scoring may be helpful in monitoring disease activity and response to treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>].CKSnotes that the retrospective recall of symptoms needed to complete a disease severity toolmay not always be reliable, especially in children and young people.</li></ul></li></ul><h5>Arranging urgent hospital admission</h5><ul><li>People with acute severe colitis require emergency hospital admission because it may be life-threatening or they may require specialist hospital treatment for symptom control[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>].<ul><li>The ECCO consensus guideline on diagnosis and management notes that immediate hospital admission is neededfor all people fulfilling criteria for severe colitis, to prevent delayed decision-making which may lead to increased peri-operative morbidity and mortality [<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li><li>The joint ECCO/ESPGHAN guideline notes that, with few exceptions, children with acute severe colitis should be admitted to hospital for immediate evaluation and intensive medical treatment with intravenous corticosteroids to induce remission. In addition, alternative diagnoses such as toxic megacolon or bowel perforation should be excluded if there is severe or escalating abdominal pain [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>].</li><li>This approach is supported by the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>] that intravenous corticosteroids, rescue therapy with infliximab or ciclosporin,or early surgical intervention may be needed.</li></ul></li></ul><h5>Management if admission not indicated</h5><ul><li>The recommendation to exclude alternative causes for symptoms suggesting a disease flare-up such as checking for <em>Clostridium difficile</em> infection is based on the ECCO consensus guidelines [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>] andexpert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fell, 2016</a>].<ul><li>Ulcerative colitis is an independent risk factor for infection with <em>C.</em><em>difficile</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>].</li><li>The joint ECCO/ESPGHAN guideline on management notes that enteric infectionsand adverse effects ofmedications (primarily mesalazine and thiopurines) can mimic acute severe colitis and need to be excluded [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>].</li><li>The ECCO consensus guideline on current management notes that causes of refractory disease include poor adherence to therapy, unrecognised complications, or an inappropriate diagnosis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>].</li></ul></li><li>The recommendation toarrangean urgentgastroenterology review appointment or seekspecialist advice is based on the ECCO consensus guideline on management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>]and theBSGguideline, which states that people experiencing a possible relapse ofinflammatory bowel disease should have access to specialist review within five working days [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>]. It is also extrapolated from expert opinion in a review article which states a person's specialist should be contactedin the event of a relapse of ulcerative colitis [<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>].</li><li>The information onconsidering starting oral corticosteroids in primary care is extrapolated from the ECCO consensus guideline on management, which states that systemic corticosteroids are appropriate in people with moderate to severe disease activity and in those with mild activity who do not respond to oral mesalazine [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>].</li><li>The recommendation that nonsteroidal anti-inflammatory drugs (NSAIDs) should be avoided in acute severe colitis is based on the ECCO consensus guideline on diagnosis and management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Magro, 2017</a>]and the joint ECCO/ESPGHAN guideline on management of acute severe colitis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>].</li><li>The recommendation to considerreferral to a dietitian is extrapolated from the ESPEN guideline, which states that nutritional care is important, particularly in children, to promote optimal growth and pubertal development [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>].</li></ul><h5>Management of recurrent flares of disease activity</h5><ul><li>Therecommendation to seek specialist advice is based on the NICE clinical guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>] and the joint ECCO/ESPGHAN guideline on management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>], and is also extrapolated from the ECCO consensus guideline on current management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>]. This is supported by expert opinion in the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>] and inreview articles[<a class="bibliography-reference internal-reference" href="../../references/index.html">Ford, 2013</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>].<ul><li>Elective colectomysurgery may be curative (with ileostomy or ileo-anal pouch) and this may be appropriatefor unresponsive or frequently relapsing disease that is affecting the person'squality of life[<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>]. The joint ECCO/ESPGHAN guideline notes that elective colectomy should be considered in children with activeor corticosteroid-dependent ulcerative colitis despite optimized medical therapy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018a</a>].</li><li>Surgical intervention may be indicated if disease is not responding to intensive medical therapy, if there is poorly controlled disease, or if there are recurrent flare-ups [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Rosen, 2015</a>].</li></ul></li></ul><!-- end field 920ba5a6-dde7-41b4-ab08-aa150160c4b2 --><!-- end item 4f478c7c-8a4e-4528-85d2-aa150160c4b2 --></div></section></section><section aria-labelledby="management-of-symptoms" class="ChapterBody-module--wrapper--2HCfk "><h3 id="management-of-symptoms">How shouldI manage symptoms of ulcerative colitis?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e12bdb4e-f3f0-419d-818c-4dc9124c084e --><!-- begin field 11a61371-3c9f-4ead-8b55-75d78cbbddf1 --><p><strong>If a person with ulcerative colitis has troublesome symptoms, ensure that <a class="topic-reference internal-reference" href="index.html#specialist-treatments">maintenance treatment</a> is optimal by seeking specialist advice if necessary. The following management strategies may be appropriate in primary care or according to the person's shared-care agreement, depending on clinical judgement.</strong></p><h4>Diarrhoea</h4><ul><li>Exclude any <a class="topic-reference internal-reference" href="../../diagnosis/differential-diagnosis/index.html">alternative cause</a>fordiarrhoea symptoms, such as infection, abscess formation, dysmotility,bacterial overgrowth, or bile salt malabsorption (typically causes watery diarrhoea accompanied by abdominal bloating and steatorrhoea), and manage appropriately.<ul><li>Diarrhoea may be secondary to drug treatment, such aslaxatives, iron supplements, antibiotics, azathioprine, mercaptopurine, ormethotrexate. Seek specialist advice regarding reducing or stopping medication,if necessary.</li><li>Do not prescribe anti-motility drugs such as loperamide (unless advised by a specialist) as they do not usually reduce stool frequency and can increase the risk of <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">toxic megacolon</a>.</li></ul></li><li>Offer sources of information to help manage symptoms, such as the Crohn's and Colitis UK patient informationsheets<a data-hyperlink-id="c7e6ecea-33a0-444c-9b25-a98f013a8086" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/diarrhoea-and-constipation.pdf" target="_blank">Diarrhoea and constipation</a>,<a data-hyperlink-id="b471f138-ccf5-45dc-ad27-a98f013a809b" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/managing-bowel-incontinence-in-IBD.pdf" target="_blank">Managing bowel incontinence in IBD</a>, and <a data-hyperlink-id="9164549b-974c-4486-ae77-aa3c0174e326" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/Bloating-and-Wind.pdf" target="_blank">Bloating and wind</a>.</li></ul><h4>Constipation</h4><ul><li>Assess for<a class="topic-reference internal-reference" href="../../background-information/complications/index.html">bowel obstruction</a>as an underlying cause,and if suspected, arrange emergency hospital admission.</li><li>If bowel obstruction is unlikely, ensure that the diet includes adequate fluid and soluble fibre, and warn that soluble fibre sometimes increases bloating and distension.<ul><li>Offer sources of information to help manage symptoms, such as the Crohn's and Colitis UK patient information sheet <a data-hyperlink-id="16d2272c-a7ed-450f-8f56-aa3c0174e338" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/diarrhoea-and-constipation.pdf" target="_blank">Diarrhoea and constipation</a> andbooklet<a data-hyperlink-id="c7317353-0aa4-4094-94ed-aa3c0174e346" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/Food.pdf" target="_blank">Food. Your guide</a>.</li></ul></li><li>If symptoms persist despite dietary advice, consider offering a bulk-forming laxative, such as ispaghula husk, methylcellulose, or sterculia (all soluble fibre products). Do not prescribe other types of laxatives.</li><li>Seek specialist gastroenterologyadvice if these measures are ineffective.</li></ul><h4>Abdominal pain</h4><ul><li>Identify the underlying cause ofabdominal pain if possible, to allow appropriate management.<ul><li>Persistent or recurrent abdominal pain is common in ulcerative colitis and may be caused by inflammatory exacerbations and poor disease control, intestinal dilatation, bowel obstruction, or rarely, adhesions.</li></ul></li><li>Offer analgesia for symptom relief. See the CKS topic on<a class="topic-reference external-reference" href="../../../analgesia-mild-to-moderate-pain/index.html">Analgesia - mild-to-moderate pain</a> for more information.<ul><li>Consider paracetamol first-line.</li><li>Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) as they may aggravate colitis symptoms.</li><li>Be aware that opiate analgesia may increase the risk of developing <a class="topic-reference internal-reference" href="../../background-information/complications/index.html">toxic megacolon</a>.</li></ul></li></ul><h4>Fatigue</h4><ul><li>Exclude any alternative or contributing cause for persistent fatigue, in addition to active disease, and manage appropriately.<ul><li>Additional causes includepain, anaemia,reducednutritional intake and activity levels, sleep disturbance, stress,anxiety, anddepression.See the CKS topics on<a class="topic-reference external-reference" href="../../../tiredness-fatigue-in-adults/index.html">Tiredness/fatigue in adults</a>,<a class="topic-reference external-reference" href="../../../insomnia/index.html">Insomnia</a>,<a class="topic-reference external-reference" href="../../../generalized-anxiety-disorder/index.html">Generalized anxiety disorder</a>,<a class="topic-reference external-reference" href="../../../depression/index.html">Depression</a>, and<a class="topic-reference external-reference" href="../../../depression-in-children/index.html">Depression in children</a>for more information.</li><li>Consider checking serum full blood count, ferritin,vitaminB<sub>12</sub>and folate levels, as people withulcerative colitis can develop iron deficiency anaemia due to blood loss or decreased absorption;anaemia of chronic disease;anaemia secondary to nutritional deficiencies;or drug-induced anaemia secondary tomercaptopurine,azathioprine, or sulfasalazine, for example. See the CKS topics on<a class="topic-reference external-reference" href="../../../anaemia-iron-deficiency/index.html">Anaemia - iron deficiency</a>,<a class="topic-reference external-reference" href="../../../anaemia-b12-folate-deficiency/index.html">Anaemia - B12 and folate deficiency</a>, and<a class="topic-reference external-reference" href="../../../dmards/index.html">DMARDs</a>for more information. Be aware that the optimal management of anaemia of chronic disease involves induction of remission of ulcerative colitis.</li></ul></li><li>Offer sources of information, such as the Crohn's and Colitis UK patient informationsheet<a data-hyperlink-id="73269e37-5d93-4720-a9e8-a98f013a80e1" href="http://s3-eu-west-1.amazonaws.com/files.crohnsandcolitis.org.uk/Publications/fatigue-and-IBD.pdf" target="_blank">Fatigue and IBD</a>.</li></ul><h4>Oral problems</h4><ul><li>If the person develops suspected oral lesions secondary to ulcerative colitis, such as persistent aphthous ulcers, arrange referral to a specialist in oral medicine, depending on clinical judgement. See the CKS topic on<a class="topic-reference external-reference" href="../../../aphthous-ulcer/index.html">Aphthous ulcer</a>for more information.</li></ul><!-- end field 11a61371-3c9f-4ead-8b55-75d78cbbddf1 --><!-- end item e12bdb4e-f3f0-419d-818c-4dc9124c084e --></div><section aria-labelledby="basis-for-recommendation-2ef" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-2ef">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 2efb9640-c373-47e0-a626-121f489bd7dd --><!-- begin field 784a46e6-a97b-40d9-b030-444190fc93fd --><p>Therecommendations on the management of symptoms are largely based on the National Institute for Health and Care Excellence (NICE)clinical guideline<em>Ulcerative Colitis: management</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2019</a>], the European Crohn's and Colitis Organisation (ECCO) consensus guidelines<em>Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: Current management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Harbord, 2017</a>],<em>European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Dignass, 2015</a>],and<em>Practical guideline for fatigue management in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>];thejoint ECCO andEuropean Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) evidence-based guideline<em>Management of Paediatric Ulcerative Colitis, Part 2: Acute severe colitis</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>], the British Society of Gastroenterology (BSG)<em>Guidelines for the management of inflammatory bowel disease in adults</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], the British Society of Paediatric Gastroenterology, Hepatology, and Nutrition (BSPGHAN) consensus document<em>Guidelines for the management of inflammatory bowel disease in children in the United Kingdom</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">British Society of Paediatric Gastroenterology, 2010</a>], the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline<em>Clinical nutrition in inflammatory bowel disease</em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>],and expert opinion inreview articles on ulcerative colitis[<a class="bibliography-reference internal-reference" href="../../references/index.html">Collins and Rhodes, 2006</a>]and oninflammatory bowel disease[<a class="bibliography-reference internal-reference" href="../../references/index.html">Shah and Hanauer, 2007</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Kefalakes et al, 2009</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Oliveira, 2017</a>].</p><h5>Management of diarrhoea</h5><ul><li>These recommendations are based on the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>], the ESPEN guideline on nutrition [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>], and expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Shah and Hanauer, 2007</a>].Theyare also pragmatic,based on what CKS considers to be good clinical practice.</li></ul><h5>Management of constipation</h5><ul><li>The recommendation to increasethe amount of soluble fibre in the diet is based on the ESPEN guideline on nutrition [<a class="bibliography-reference internal-reference" href="../../references/index.html">Forbes, 2017</a>], and is pragmatic, based on what CKS considers to be good clinical practice.</li><li>The recommendation tousebulk-forming laxativesis based on expert opinion in a review article which suggeststhat proximal constipation may be relieved by bulk-forming laxatives [<a class="bibliography-reference internal-reference" href="../../references/index.html">Collins and Rhodes, 2006</a>]. The British National Formulary (BNF) notes that other types of laxatives (including macrogols and sodium picosulfate) are contraindicated for use in severe inflammatory bowel disease, as they increase intestinal motility and often cause abdominal pain [<a class="bibliography-reference internal-reference" href="../../references/index.html">Joint Formulary Committee, 2019</a>].</li></ul><h5>Management of abdominal pain</h5><ul><li>The information that persistent or recurrent pain may indicate poor disease control is based on the BSPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">British Society of Paediatric Gastroenterology, 2010</a>]and the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>].</li><li>The recommendations to offer paracetamol andavoid nonsteroidal anti-inflammatory drugs (NSAIDs) which may exacerbate colitis symptoms arebased on the joint ECCO/ESPGHAN guideline[<a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>] andthe BSGguideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>]. The information about the risks of NSAID use is supported by expert opinion in a review article [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kefalakes et al, 2009</a>].</li><li>The recommendation to avoid opiate analgesiais based on the fact it can affect bowel motility and lead to stasis and toxic megacolon[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Turner, 2018b</a>].</li></ul><h5>Management of fatigue</h5><ul><li><p>Theserecommendations arebased on the ECCO consensus guidelines on iron deficiency and anaemia [<a class="bibliography-reference internal-reference" href="../../references/index.html">Dignass, 2015</a>]and fatigue management [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>], and the BSG guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>]. They are supported bythe expert opinion of previous external reviewers of this CKStopic.</p><ul><li><p>The ECCO consensus guideline on fatigue management notes thatinflammatory bowel disease-related fatigue is an underdiagnosed and undertreated issue inclinical practice with a severe negative effect on the person's quality of life. Many factors are known to contribute to fatigue, such as inflammation, pain, emotional distress, sleep disturbance, anaemia, alterations in nutrition and overall nutritional status, and reduced activity levels.In addition, adverse effects of medications andalcohol and/or drug misuse may be relevant [<a class="bibliography-reference internal-reference" href="../../references/index.html">Kreijne, 2016</a>].</p></li><li><p>The information on possible medications causing drug-induced anaemia is based on the BSG guideline.</p></li></ul></li></ul><h5>Management of oral problems</h5><ul><li><p>Thisrecommendationis based on the BSPGHAN guideline [<a class="bibliography-reference internal-reference" href="../../references/index.html">British Society of Paediatric Gastroenterology, 2010</a>] and theBSG guideline[<a class="bibliography-reference internal-reference" href="../../references/index.html">Mowat et al, 2011</a>]. It is also pragmatic, based on what CKS considers to be good clinical practice.</p></li></ul><!-- end field 784a46e6-a97b-40d9-b030-444190fc93fd --><!-- end item 2efb9640-c373-47e0-a626-121f489bd7dd --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI"><!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/ulcerative-colitis/management/confirmed-ulcerative-colitis/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>